CIK 0001488039 · Non-accelerated filer<br>Smaller reporting company
ATOSSA THERAPEUTICS, INC.
Sign in to watch- Ticker
- ATOS
- Exchange
- Nasdaq
- Industry
- Pharmaceutical Preparations
- FY end
- Dec 31
- Incorporated
- DE
- Entity type
- operating
- EIN
- 264753208
- Phone
- 206.588.0256
- Business address
- 1448 NW MARKET STREET, SUITE 500, SEATTLE, WA, 98107
- Former names
- ATOSSA GENETICS INC
- Open-market buys, last 90 days
- $0
- in 0 filings
- Open-market sales, last 90 days
- $0
- in 0 filings
Shares bought or sold at a price by officers, directors and 10% owners (Form 4 codes P and S). Grants, option exercises and tax withholding aren't counted.
| Date | Insider | Transaction | Shares | Price | Value | Owned after |
|---|---|---|---|---|---|---|
| 2026-05-12 | Steinhart Richard I Director | Grant or award | +10,000 | 10,000 | ||
| 2026-05-12 | Chen Shu-Chih Director | Grant or award | +10,000 | 10,000 | ||
| 2026-05-12 | Remmel H. Lawrence Director | Grant or award | +10,000 | 10,683 | ||
| 2026-05-12 | Finn Jonathan Director | Grant or award | +10,000 | 11,666 | ||
| 2026-05-12 | Galli Stephen J Director | Grant or award | +10,000 | 10,006 | ||
| 2026-05-12 | Cigler Tessa Director | Grant or award | +10,000 | 10,000 | ||
| 2026-03-27 | QUAY STEVEN C President & CEO | Grant or award | +65,000 | 88,038 | ||
| 2026-03-26 | Daniel Mark James Chief Financial Officer | Grant or award | +63,000 | 63,000 | ||
| 2026-01-20 | QUAY STEVEN C President & CEO | Grant or award | +331,674 | 345,572 | ||
| 2026-01-20 | QUAY STEVEN C President & CEO | Grant or award · Stock Options (right to buy) | +950,000 | $0.60 | $573K | 950,000 |
| 2026-01-20 | QUAY STEVEN C President & CEO | Grant or award | +325,203 | 339,101 | ||
| 2026-01-20 | QUAY STEVEN C President & CEO | Grant or award · Stock Options (right to buy) | +950,000 | $0.60 | $573K | 950,000 |
| 2025-10-14 | Daniel Mark James Chief Financial Officer | Grant or award · Stock Option (right to buy) | +578,000 | 578,000 | ||
| 2025-05-21 | QUAY STEVEN C President & CEO | Purchase | +11,239 | $0.88 | $10K | 13,898 |
| 2025-05-15 | Finn Jonathan Director | Grant or award · Stock Option (right to buy) | +125,000 | 125,000 | ||
| 2025-05-15 | Chen Shu-Chih Director | Grant or award · Stock Option (right to buy) | +125,000 | 125,000 | ||
| 2025-05-15 | QUAY STEVEN C President & CEO | Grant or award · Stock Option (right to buy) | +1,366,062 | 1,366,062 | ||
| 2025-05-15 | Rees Heather Chief Financial Officer | Grant or award · Stock Option (right to buy) | +543,785 | 543,785 | ||
| 2025-05-15 | Galli Stephen J Director | Grant or award · Stock Option (right to buy) | +125,000 | 125,000 | ||
| 2025-05-15 | Remmel H. Lawrence Director | Grant or award · Stock Option (right to buy) | +125,000 | 125,000 |
Page 1 of 9 · 168 trades